<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34349004</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Plasma NfL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i>-associated diseases: from tailored references to clinical applications.</ArticleTitle><Pagination><StartPage>1278</StartPage><EndPage>1288</EndPage><MedlinePgn>1278-1288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2021-326914</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Neurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in <i>C9orf72</i> and <i>GRN</i> cohorts from presymptomatic to clinical stages.</AbstractText><AbstractText Label="METHODS">We analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of <i>C9orf72</i> and <i>GRN</i> patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of &gt;2&#x2009;years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical-genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index.</AbstractText><AbstractText Label="RESULTS">pNfL levels increased with age in controls, from ~5&#x2009;to~18&#x2009;pg/mL (p&lt;0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p&lt;0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p&lt;0.0001), with gene-specific trajectories. <i>GRN</i> patients had higher levels than <i>C9orf72</i> (86.21 vs 39.49&#x2009;pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In <i>C9orf72</i> patients, levels were associated with the phenotype (ALS: 71.76&#x2009;pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades.</AbstractText><AbstractText Label="CONCLUSIONS">This study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBERS">NCT02590276 and NCT04014673.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saracino</LastName><ForeName>Dario</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4299-9743</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aramis Project Team, Inria Paris Research Centre, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorgham</LastName><ForeName>Karim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-9539-3203</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, INSERM, Centre d'Immunologie et des Maladies Infectieuses-Paris (CIMI-Paris), Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>EPHE, PSL Research University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rametti-Lacroux</LastName><ForeName>Armelle</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houot</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre of Excellence of Neurodegenerative Disease (CoEN), ICM, CIC Neurosciences, D&#xe9;partement de Neurologie, AP-HP, H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Sorbonne Universit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clot</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>UF de Neurog&#xe9;n&#xe9;tique Mol&#xe9;culaire et Cellulaire, D&#xe9;partement de G&#xe9;n&#xe9;tique, AP-HP, H&#xf4;pitaux Universitaires La Piti&#xe9; Salp&#xea;tri&#xe8;re-Charles Foix, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin-Hardy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jornea</LastName><ForeName>Ludmila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azuar</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migliaccio</LastName><ForeName>Raffaella</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6960-8474</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Univ Lille, Inserm U1171, CHU Lille, DistAlz, LiCEND, CNR-MAJ, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CMRR Service de Neurologie, CHU de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Auriacombe</LastName><ForeName>Sophie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CMRR Nouvelle Aquitaine, Institut des Maladies Neurod&#xe9;g&#xe9;n&#xe9;ratives Clinique (IMNc), CHU de Bordeaux H&#xf4;pital Pellegrin, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauv&#xe9;e</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CMRR de l'Arc Alpin, POLE PR&#xe9;NeLE, CHU Grenoble Alpes, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boutoleau-Bretonni&#xe8;re</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHU Nantes, Inserm CIC04, Department of Neurology, Centre M&#xe9;moire de Ressources et Recherche, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Toulouse University Hospital, Toulouse, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Toulouse NeuroImaging Centre (ToNIC), Inserm, UPS, University of Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Didic</LastName><ForeName>Mira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>APHM, Timone, Service de Neurologie et Neuropsychologie, H&#xf4;pital Timone Adultes, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut de Neurosciences des Syst&#xe8;mes (INS), Aix-Marseille University, Inserm, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and CNR-MAJ, Normandy Center for Genomic and Personalized Medicine, Normandie University, UNIROUEN, Inserm U1245 and Rouen University Hospital, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Research Network on FTD/FTD-ALS</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PREV-DEMALS and Predict-PGRN study groups</CollectiveName></Author><Author ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aramis Project Team, Inria Paris Research Centre, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forlani</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2508-5181</Identifier><AffiliationInfo><Affiliation>Sorbonne Universit&#xe9;, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France isabelle.leber@upmc.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Reference Centre for Rare or Early Dementias, IM2A, D&#xe9;partment de Neurologie, AP-HP - H&#xf4;pital Piti&#xe9;-Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inserm U 1127, CNRS UMR 7225, Sorbonne Universit&#xe9;, Paris Brain Institute-Institut du Cerveau (ICM), FRONTlab, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04014673</AccessionNumber><AccessionNumber>NCT02590276</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492314">GRN protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077153">Progranulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077153" MajorTopicYN="N">Progranulins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: Disclosure of interests unrelated to the present article: ILB served as a member of advisory board for Prevail Therapeutics and of the steering committee for Alector, and received research grants from ANR, DGOS, PHRC, ARSla Association, Fondation Plan Alzheimer outside of the present work.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Auriacombe</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belliard</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanc</LastName><ForeName>Fr&#xe9;d&#xe9;ric</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutoleau-Bretonni&#xe8;re</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceccaldi</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Didic</LastName><ForeName>Mira</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duyckaerts</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Etcharry-Bouyx</LastName><ForeName>Fr&#xe9;d&#xe9;rique</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Formaglio</LastName><ForeName>Ma&#xef;t&#xe9;</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golfier</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacomblez</LastName><ForeName>Lucette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ber</LastName><ForeName>Isabelle Le</ForeName><Initials>IL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michel</LastName><ForeName>Bernard-Fran&#xe7;ois</ForeName><Initials>BF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sauv&#xe9;e</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sellal</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thauvin-Robinet</LastName><ForeName>Christel</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas-Anterion</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vercelletto</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auffray-Calvier</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardinet</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benchetrit</LastName><ForeName>Eve</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berry</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertin</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bissery</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bombois</LastName><ForeName>St&#xe9;phanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boncoeur</LastName><ForeName>Marie-Paule</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutoleau-Bretonni&#xe8;re</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camuzat</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Causse-Lemercier</LastName><ForeName>Val&#xe9;rie</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chastan</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Yaohua</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chupin</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colliot</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delbeuck</LastName><ForeName>Xavier</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delmaire</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deramecourt</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Didic</LastName><ForeName>Mira</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Funkiewiez</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerardin</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girard</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guedj</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habert</LastName><ForeName>Marie-Odile</ForeName><Initials>MO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannequin</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kas</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuchinski</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lautrette</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ber</LastName><ForeName>Isabelle Le</ForeName><Initials>IL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toullec</LastName><ForeName>Benjamin Le</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackowiak</LastName><ForeName>Marie-Anne</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masmanian</LastName><ForeName>Merry</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monteil</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oya</LastName><ForeName>Assi-Herv&#xe9;</ForeName><Initials>AH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pallardy</LastName><ForeName>Amandine</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pariente</LastName><ForeName>J&#xe9;r&#xe9;mie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petyt</LastName><ForeName>Gr&#xe9;gory</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payoux</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Daisy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rollin-Sillaire</LastName><ForeName>Adeline</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sayah</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallon</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34349004</ArticleId><ArticleId IdType="pmc">PMC8606463</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2021-326914</ArticleId><ArticleId IdType="pii">jnnp-2021-326914</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baker M, Mackenzie IR, Pickering-Brown SM, et al. . Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916&#x2013;9. 10.1038/nature05016</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05016</ArticleId><ArticleId IdType="pubmed">16862116</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, van der Zee J, et al. . Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920&#x2013;4. 10.1038/nature05017</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05017</ArticleId><ArticleId IdType="pubmed">16862115</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. . Expanded GGGGCC hexanucleotide repeat in noncoding region of C9orf72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245&#x2013;56. 10.1016/j.neuron.2011.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257&#x2013;68. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Nicholas J, Grossman M, et al. . Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurol 2020;19:145&#x2013;56. 10.1016/S1474-4422(19)30394-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30394-1</ArticleId><ArticleId IdType="pmc">PMC7007771</ArticleId><ArticleId IdType="pubmed">31810826</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. . Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9orf72 mutations. Brain 2012;135:693&#x2013;708. 10.1093/brain/awr355</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr355</ArticleId><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan BK, Yokoyama JS, Takada LT, et al. . Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion. J Neurol Neurosurg Psychiatry 2012;83:358&#x2013;64. 10.1136/jnnp-2011-301883</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-301883</ArticleId><ArticleId IdType="pmc">PMC3388906</ArticleId><ArticleId IdType="pubmed">22399793</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente ES, Caramelli P, Gambogi LB, et al. . Phenocopy syndrome of behavioral variant frontotemporal dementia: a systematic review. Alzheimers Res Ther 2019;11:30. 10.1186/s13195-019-0483-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0483-2</ArticleId><ArticleId IdType="pmc">PMC6444822</ArticleId><ArticleId IdType="pubmed">30935398</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, et al. . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577&#x2013;89. 10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, et al. . Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 2019;90:870&#x2013;81. 10.1136/jnnp-2018-320106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. . Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019;76:1035. 10.1001/jamaneurol.2019.1534</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1534</ArticleId><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, et al. . Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 2016;3:623&#x2013;36. 10.1002/acn3.325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.325</ArticleId><ArticleId IdType="pmc">PMC4999594</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Anderl-Straub S, Diehl-Schmid J, et al. . Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology 2018;91:e1390&#x2013;401. 10.1212/WNL.0000000000006318</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006318</ArticleId><ArticleId IdType="pubmed">30209235</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, et al. . Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurol 2019;18:1103&#x2013;11. 10.1016/S1474-4422(19)30354-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30354-0</ArticleId><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Benussi A, Karikari TK, Ashton N, et al. . Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2020;91:960&#x2013;7. 10.1136/jnnp-2020-323487</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323487</ArticleId><ArticleId IdType="pubmed">32611664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajanus A, Katisko K, Kontkanen A, et al. . Serum neurofilament light chain in FTLD: association with C9orf72, clinical phenotype, and prognosis. Ann Clin Transl Neurol 2020;7:903&#x2013;10. 10.1002/acn3.51041</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51041</ArticleId><ArticleId IdType="pmc">PMC7318100</ArticleId><ArticleId IdType="pubmed">32441885</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Huss A, Mayer B, et al. . Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND-net. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:112&#x2013;9. 10.1080/21678421.2016.1241279</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1241279</ArticleId><ArticleId IdType="pubmed">27819158</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, et al. . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157&#x2013;64. 10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Zhang L, Wang L, et al. . Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 2020;95:e59&#x2013;69. 10.1212/WNL.0000000000009559</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener 2019;20:538&#x2013;48. 10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas JC, Wang P, Staffaroni AM, et al. . Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 2021;96:e2296&#x2013;312. 10.1212/WNL.0000000000011848</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011848</ArticleId><ArticleId IdType="pmc">PMC8166434</ArticleId><ArticleId IdType="pubmed">33827960</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, Guedj E, Gabelle A, et al. . Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006;129:3051&#x2013;65. 10.1093/brain/awl288</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl288</ArticleId><ArticleId IdType="pubmed">17071924</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P, Habert M-O, Durrleman S, et al. . Lateral temporal lobe: an early imaging marker of the presymptomatic GRN disease? J Alzheimers Dis 2015;47:751&#x2013;9. 10.3233/JAD-150270</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150270</ArticleId><ArticleId IdType="pmc">PMC4923734</ArticleId><ArticleId IdType="pubmed">26401709</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand A, Wen J, Rinaldi D, et al. . Early Cognitive, Structural, and Microstructural Changes in Presymptomatic C9orf72 Carriers Younger Than 40 Years. JAMA Neurol 2018;75:236. 10.1001/jamaneurol.2017.4266</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.4266</ArticleId><ArticleId IdType="pmc">PMC5838615</ArticleId><ArticleId IdType="pubmed">29197216</ArticleId></ArticleIdList></Reference><Reference><Citation>Kmetzsch V, Anquetil V, Saracino D, et al. . Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2021;92:485&#x2013;93. 10.1136/jnnp-2020-324647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-324647</ArticleId><ArticleId IdType="pmc">PMC8053348</ArticleId><ArticleId IdType="pubmed">33239440</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenney EM, Ahmed RM, Halliday G, et al. . Psychiatric disorders in C9orf72 kindreds: study of 1,414 family members. Neurology 2018;91:e1498&#x2013;507. 10.1212/WNL.0000000000006344</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006344</ArticleId><ArticleId IdType="pubmed">30258023</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Boill&#xe9;e S, Le Ber I, et al. . Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 2012;49:258&#x2013;63. 10.1136/jmedgenet-2011-100699</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2011-100699</ArticleId><ArticleId IdType="pubmed">22499346</ArticleId></ArticleIdList></Reference><Reference><Citation>Cammack AJ, Atassi N, Hyman T, et al. . Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology 2019;93:10.1212/WNL.0000000000008359. 10.1212/WNL.0000000000008359</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008359</ArticleId><ArticleId IdType="pmc">PMC6946465</ArticleId><ArticleId IdType="pubmed">31578300</ArticleId></ArticleIdList></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et al. . Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med 2019;25:277&#x2013;83. 10.1038/s41591-018-0304-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0304-3</ArticleId><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, et al. . Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 2016;79:152&#x2013;8. 10.1002/ana.24552</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Zetterberg H, et al. . Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2017;74:557. 10.1001/jamaneurol.2016.6117</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.6117</ArticleId><ArticleId IdType="pmc">PMC5822204</ArticleId><ArticleId IdType="pubmed">28346578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lle&#xf3; A, Alcolea D, Mart&#xed;nez-Lage P, et al. . Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimers Dement 2019;15:742&#x2013;53. 10.1016/j.jalz.2019.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2019.01.015</ArticleId><ArticleId IdType="pubmed">30967340</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Pirpamer L, Hofer E, et al. . Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 2020;11:812. 10.1038/s41467-020-14612-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14612-6</ArticleId><ArticleId IdType="pmc">PMC7010701</ArticleId><ArticleId IdType="pubmed">32041951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Oeckl P, Amador MDM, et al. . A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotroph Lateral Scler Frontotemporal Degener 2020;21:1&#x2013;7. 10.1080/21678421.2020.1779300</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1779300</ArticleId><ArticleId IdType="pubmed">32558597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Cullen NC, Andreasson U, et al. . Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol 2019;76:791. 10.1001/jamaneurol.2019.0765</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.0765</ArticleId><ArticleId IdType="pmc">PMC6583067</ArticleId><ArticleId IdType="pubmed">31009028</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P, Le Ber I, Camuzat A, et al. . Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin. JAMA Neurol 2014;71:1562. 10.1001/jamaneurol.2014.1316</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1316</ArticleId><ArticleId IdType="pubmed">25317628</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Bocchetta M, Heller C, et al. . White matter hyperintensities in progranulin-associated frontotemporal dementia: a longitudinal GENFI study. Neuroimage 2019;24:102077. 10.1016/j.nicl.2019.102077</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.102077</ArticleId><ArticleId IdType="pmc">PMC6911860</ArticleId><ArticleId IdType="pubmed">31835286</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, et al. . Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22&#x2013;30. 10.1212/WNL.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Shweiki MHDR, Steinacker P, Oeckl P, et al. . Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res 2019;113:137&#x2013;40. 10.1016/j.jpsychires.2019.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.03.019</ArticleId><ArticleId IdType="pubmed">30953863</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourier A, Formaglio M, Kaczorowski F, et al. . A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders. Eur J Neurol 2020;27:1164&#x2013;9. 10.1111/ene.14247</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14247</ArticleId><ArticleId IdType="pubmed">32243670</ArticleId></ArticleIdList></Reference><Reference><Citation>Panman JL, Venkatraghavan V, van der Ende EL, et al. . Modelling the cascade of biomarker changes in GRN -related frontotemporal dementia. J Neurol Neurosurg Psychiatry 2021;92:494&#x2013;501. 10.1136/jnnp-2020-323541</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323541</ArticleId><ArticleId IdType="pmc">PMC8053353</ArticleId><ArticleId IdType="pubmed">33452053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the genetic frontotemporal dementia initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015;14:253&#x2013;62. 10.1016/S1474-4422(14)70324-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70324-2</ArticleId><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SE, Sias AC, Mandelli ML, et al. . Network degeneration and dysfunction in presymptomatic C9ORF72 expansion carriers. Neuroimage 2017;14:286&#x2013;97. 10.1016/j.nicl.2016.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2016.12.006</ArticleId><ArticleId IdType="pmc">PMC5349617</ArticleId><ArticleId IdType="pubmed">28337409</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Blanc G, Jett&#xe9; Pomerleau V, McCarthy J, et al. . Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Ann Neurol 2020;88:113&#x2013;22. 10.1002/ana.25748</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25748</ArticleId><ArticleId IdType="pubmed">32285980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>